Date: 2015-05-14
Type of information: R&D agreement
Compound: immunological therapies targeting multiple immune checkpoint modulators
Company: Eli Lilly (USA - IN) Sanford-Burnham Medical Research Institute (USA - CA)
Therapeutic area: Autoimmune diseases – Immunological diseases
Type agreement: R&D
Action mechanism:
Disease: lupus, Sjögren\'s Syndrome, inflammatory bowel disease and other autoimmune disorders
Details: * On May 14, 2015, Eli Lilly and Sanford-Burnham Medical Research Institute announced that they will collaborate to discover and develop immunological therapies. Lilly and Sanford-Burnham, a non-profit medical research institute, will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren\'s Syndrome, inflammatory bowel disease and other autoimmune disorders. The comprehensive research collaboration is driven by Lilly\'s world-class biotechnology capabilities and expertise in immunology, and Sanford-Burnham\'s deep expertise in understanding the fundamental cellular pathways regulating the immune system focusing on the immune checkpoint networks. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F. Bumol, Ph.D., senior vice president, biotechnology and immunology research at Lilly, and Carl Ware, Ph.D., director, Infectious and Inflammatory Diseases Center at Sanford-Burnham.
Financial terms:
Latest news:
